European Private Equity Firm Astorg has unveiled Nexpring Health, a new global medtech company dedicated to Assisted Reproductive Technology (ART). The company emerges from strategic acquisitions of Hamilton Thorne, Cook Medical’s Reproductive Health business, and the upcoming acquisition of FUJIFILM Irvine Scientific’s Medical Media Business.
Leveraging 40 years of reproductive medicine expertise, Nexpring Health aims to address rising infertility rates and support fertility clinics through a comprehensive ecosystem of solutions. The company offers one of the most comprehensive ART solutions portfolios in the industry, designed to empower embryologists, clinicians, and fertility clinics worldwide.
Wil Boren, Chief Executive Officer of Nexpring Health, commented: “We firmly believe that the greatest impact on patient outcomes comes from empowering the professionals at the heart of fertility clinics – embryologists and clinicians. Our approach is deeply collaborative, working closely with these experts to understand their daily challenges and develop solutions that enhance their capabilities.
“With Astorg’s support, Nexpring Health is uniting decades of innovation and expertise to serve a vision and purpose: to remove complexity and create a comprehensive ecosystem of solutions that addresses the full spectrum of professionals’ needs. Every advancement we make is designed with the fertility clinic workflow at the center of our approach. That’s what sets Nexpring Health apart.”
The company has appointed a new board of directors, including:
- Thomas Axelsson as Non-executive Chairman
- John Enneking as Board Member
- Vivid Sehgal as Board Member
Judith Charpentier, Co-Head of Flagship Fund and Head of Healthcare at Astorg, shared: “Nexpring Health is the result of a bold, creative investment strategy and a strong shared vision with Wil – built on Astorg’s deep expertise in MedTech and long-term partnership mindset. Our ambition is clear: work alongside a talented team with the expertise, purpose, and momentum to advance reproductive health.”
Nexpring Health emphasizes operational continuity, assuring customers they can expect the same high-quality products, expert support, and seamless ordering processes. The company is committed to driving innovation and introducing solutions that simplify complex procedures while helping clinics achieve consistent outcomes.
Olivier Lieven, Partner, and Tobias Nordblom, Managing Director at Astorg, concluded: “We are proud to partner with the management team, employees and board of directors to launch Nexpring Health, a company with the scale, expertise, and distinctive product portfolio to serve the evolving needs of fertility professionals around the world.”
